Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Hialeah, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Miami, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tampa, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
W Palm Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
W Palm Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Charlotte, NC
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tulsa, OK
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Austin, TX
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
mi
from
Adelaide,
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
mi
from
Adelaide,
Click here to add this to my saved trials
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated:  2/24/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated: 2/24/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Status: Enrolling
Updated:  2/25/2016
California Clinical Trials Medical Group
mi
from
Glendale, CA
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Status: Enrolling
Updated: 2/25/2016
California Clinical Trials Medical Group
mi
from
Glendale, CA
Click here to add this to my saved trials
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study
Status: Enrolling
Updated:  2/26/2016
University of Wisconsin
mi
from
Madison, WI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study
Status: Enrolling
Updated: 2/26/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated:  3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Status: Enrolling
Updated: 3/1/2016
Sanguine Biosciences
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Naples Medical Center
mi
from
Naples, FL
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Naples Medical Center
mi
from
Naples, FL
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
University of Maryland
mi
from
Baltimore, MD
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Primary Care Cardiology Research
mi
from
Ayer, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Primary Care Cardiology Research
mi
from
Ayer, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Rivercourt Residences
mi
from
Groton, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Rivercourt Residences
mi
from
Groton, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Mary Immaculate Residential
mi
from
Lawrence, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Mary Immaculate Residential
mi
from
Lawrence, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
D'Youville Senior Care
mi
from
Lowell, MA
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
D'Youville Senior Care
mi
from
Lowell, MA
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
The NeuroCognitive Institute
mi
from
Mt. Arlington, NJ
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
The NeuroCognitive Institute
mi
from
Mt. Arlington, NJ
Click here to add this to my saved trials
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated:  3/2/2016
Advanced Memory Dynamics
mi
from
Layton, UT
A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
Status: Enrolling
Updated: 3/2/2016
Advanced Memory Dynamics
mi
from
Layton, UT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Boswell Medical Center
mi
from
Sun City, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Boswell Medical Center
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
University of California at San Francisco
mi
from
San Francisco, CA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Yale-New Haven Hospital
mi
from
New Haven, CT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Yale University School of Medicine
mi
from
New Haven, CT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
General Clinical Research Unit
mi
from
Washington,
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
General Clinical Research Unit
mi
from
Washington,
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Georgetown University Medical Center
mi
from
Washington,
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
MD Clinical
mi
from
Hallandale Beach, FL
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Brigham and Woman's Hospital
mi
from
Boston, MA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Brigham and Woman's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Center for Alzheimer Research and Treatment
mi
from
Boston, MA
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Center for Alzheimer Research and Treatment
mi
from
Boston, MA
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Barnes Jewish Hospital
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Washington University School of Medicine
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Columbia University Taub Institute
mi
from
New York, NY
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Columbia University Taub Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
CUMC Research Pharmacy
mi
from
New York, NY
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
CUMC Research Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Butler Hospital
mi
from
Providence, RI
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
Southwestern Vermont Healthcare
mi
from
Bennington, VT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
Southwestern Vermont Healthcare
mi
from
Bennington, VT
Click here to add this to my saved trials
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
The Memory Clinic
mi
from
Bennington, VT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials